Cytogenetics of melanoma and nonmelanoma skin cancer

Advances in Experimental Medicine and Biology

Volumn 624, Issue , 2008, Pages 227-240

  Griffiths, Lyn R ^a   Carless, Melanie A ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; BOWEN DISEASE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME LOSS; CYTOGENETICS; DERMATOFIBROSARCOMA PROTUBERANS; HUMAN; KERATOACANTHOMA; MELANOMA; MERKEL CELL TUMOR; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SKIN LYMPHOMA; SQUAMOUS CELL CARCINOMA; GENETICS; KARYOTYPING; SKIN TUMOR;

CHROMOSOME ABERRATIONS; CYTOGENETICS; HUMANS; KARYOTYPING; MELANOMA; SKIN NEOPLASMS;

EID: 42949158249     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-77574-6_18     Document Type: Review

References (104)

1. Albert MR, Wcinstock MA. Kcratinocytc carcinoma. CA Cancer J Clin 2003; 53(5):292-302.
2. Weinstock MA. Epidemiology of nonmelanoma skin cancer: clinical issues, definitions and classification. J Invest Dermatol 1994; 102(6):4S-5S.
3. Gloster HM, Jr. Brodland DG. The epidemiology of skin cancer. Dermatol Surg 1996; 22(3):217-226.
4. Hoglund M, Gisselsson D, Hansen GB et al. Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004; 108(l):57-65.
5. Sarasin A. The molecular pathways of ultraviolet-induced carcinogenesis. Mutat Res 1999; 428(l-2):5-10.
6. Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol 2004; 195(3):298-308.
7. Emri G, Wenczl E, Van Erp P et al. Low doses of UVB or UVA induce chromosomal aberrations in cultured human skin cells. J Invest Dermatol 2000; 115(3):435-440.
8. Jin Y, Martins C, Jin C et al. Nonrandom karyotypic features in squamous cell carcinomas of the skin. Genes Chromosomes Cancer 1999; 26(4):295-303.
9. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005; 5(10):773-785.
10. Duesberg P, Rasnick D. Aneuploidy, the somatic mutation that makes cancer a species of its own. Cell Motil Cytoskeleton 2000; 47(2):81-107.
11. Klapperstuck T, Wohlrab W. DNA image cytometry on sections as compared with image cytometry on smears and flow cytometry in melanoma. Cytometry 1996; 25(l):82-89.
12. Rapi S, Caldini A, Fanelli A et al. Flow cytometric measurement of DNA content in human solid tumors: a comparison with cytogenetics. Cytometry 1996; 26(3): 192-197.
13. Robinson JK, Rademaker AW, Goolsby C et al. DNA ploidy in nonmelanoma skin cancer. Cancer 1996; 77(2):284-291.
14. WiUiams NN, Daly JM. Flow cytometry and prognostic implications in patients with solid tumors. Surg Gynecol Obstet 1990; 171(3):257-266.
15. Chen Z, Sandberg AA. Molecular cytogenetic aspects of hematological malignancies: clinical implications. Am J Med Genet 2002; 115(3):130-141.
16. Mertens F, Heim S, Mandahl N et al. Cytogenetic analysis of 33 basal cell carcinomas. Cancer Res 1991; 51(3):954-957.
17. Lotem M, Yehuda-Gafni O, Butnaryu E et al. Cytogenetic analysis of melanoma cell lines: subclone selection in long-term melanoma cell cultures. Cancer Genet Cytogenet 2003; 142(2):87-91.
18. James L, Varley J. Advances in cytogenetic analysis of solid tumours. Chromosome Res 1996; 4(7):479-485.
19. Kallioniemi OP, Kallioniemi A, Piper J et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994; 10(4):231-243.
20. Kallioniemi A, Visakorpi T, Karhu R et al. Gene Copy Number Analysis by Fluorescence in Situ Hybridization and Comparative Genomic Hybridization. Methods 1996; 9(1):113-121.
21. Thompson CT, Gray JW. Cytogenetic profiling using fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH). J Cell Biochem Suppl 1993; 17G:139-143.
22. VarcUa-Garcia M. Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis and therapy. Oncologist 2003; 8(l):45-58.
23. Happle R. Loss of heterozygosity in hiunan skin. J Am Acad Dermatol 1999; 41(2 Pt 1): 143-164.
24. Forozan F, Mahlamaki EH, Monni O et al. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res 2000; 60(16):4519-4525.
25. Okamoto I, Pirker C, Bilban M et al. Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma. Neoplasia 2005; 7(4):303-311.
26. Platzer P, Upender MB, Wilson K et al. Silence of chromosomal amplifications in colon cancer. Cancer Res 2002; 62(4):1134-1138.
27. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005; 115(4):813-824.
28. Pollock PM, Welch J, Hayward NK. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res 2001; 61(3):1154-1161.
29. Rager EL, Bridgeford EP, OUila DW. Cutaneous melanoma: update on prevention, screening, diagnosis and treatment. Am Fam Physician 2005; 72(2):269-276.
30. Skin Cancer Foundation. The Stages of Melanoma. http://www.skincancer. Org/content/view/17/3/l/3/. Accessed 2/3/2007, 2007.
31. Clark WH, Jr. From L, Bernardino EA et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29(3):705-727.
32. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172(5) :902-908.
33. Hussein MR, Wood GS. Molecular aspects of melanocytic dysplastic nevi. J Mol Diagn 2002; 4(2):71-80.
34. von Rocnn JH, Kheir SM, Wolter JM et al. Significance of DNA abnormalities in primary malignant melanoma and nevi, a retrospective flow cytometric study. Cancer Res 1986; 46(6):3192-3195.
35. Kheir SM, Bines SD, Vonroenn JH et al. Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma. Ann Surg 1988; 207(4) :455-461.
36. Mitelman Database of Chromosome Aberrations in Cancer. In:Mitelman F, Johansson B, Mertens F. eds. 2006. http://cgap.nci.nih.gov/chromosomes/mitelman.
37. Cowan JM, Francke U. Cytogenetic analysis in melanoma and nevi. Cancer Treat Res 1991;54:3-16.
38. Marras S, Faa G, Dettori T et al. Chromosomal changes in dysplastic nevi. Cancer Genet Cytogenet 1999; 113(2):177-179.
39. Richmond A, Fine R, Murray D et al. Growth factor and cytogenetic abnormahties in cultured nevi and malignant melanomas. J Invest Dermatol 1986; 86(3):295-302.
40. Bastian BC, Olshen AB, LeBoit PE et al. Classifying melanocytic timiors based on DNA copy number changes. Am J Pathol 2003; 163(5):1765-1770.
41. Balazs M, Adam Z, Treszl A et al. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 2001; 46(4):222-232.
42. Barks JH, Thompson FH, Taetle R et al. Increased chromosome 20 copy number detected by fluorescence in situ hybridization (FISH) in malignant melanoma. Genes Chromosomes Cancer 1997; 19(4):278-285.
43. Utikal J, Udart M, Leiter U et al. Additional Cyclin D(l) gene copies associated with chromosome 11 aberrations in cutaneous malignant melanoma. Int J Oncol 2005; 26(3):597-605.
44. Udart M, Utikal J, Krahn GM et al. Chromosome 7 aneusomy. A marker for metastatic melanoma? E3q)ression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 2001; 3(3):245-254.
45. Treszl A, Adany R, Rakosy Z et al. Extra copies of c-myc are more pronounced in nodular melanomas than in superficial spreading melanomas as revealed by fluorescence in situ hybridisation. Cytometry B Clin Cytom 2004; 60(l):37-46.
46. Matsuta M, Imamura Y, Matsuta M et al. Detection of numerical chromosomal aberrations in malignant melanomas using fluorescence in situ hybridization. J Cutan Pathol 1997; 24(4) :201-205.
47. Hussein MR, Sun M, Roggero E et al. Loss of heterozygosity, microsatellite instabiUty and mismatch repair protein alterations in the radial growth phase of cutaneous malignant melanomas. Mol Carcinog 2002; 34(l):35-44.
48. Hussein MR, Roggero E, Tuthill RJ et al. Identification of novel deletion Loci at lp36 and 9p22-21 in melanocytic dysplastic nevi and cutaneous malignant melanomas. Arch Dermatol 2003; 139(6):816-817.
49. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30(5 Pt l):774-778.
50. Wong CS, Strange RC. Lear JT. Basal cell carcinoma. Bmj 2003; 327(7418):794-798.
51. Bernstein SC, Lim KK, Brodland DG et al. The many faces of squamous cell carcinoma. Dermatol Surg 1996; 22(3):243-254.
52. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146(Suppl 61): 1-6.
53. Skidmore RA, Jr. Flowers FP. Nonmelanoma skin cancer. Med Clin Nordi Am 1998; 82(6): 1309-1323, vi
54. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42(1 Pt 2):4-7.
55. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol 2000; 115(2):273-277.
56. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; l(8589):795-797.
57. Evans C, Cockerell CJ. Actinic keratosis: time to call a spade a spade. South Med J 2000; 93(7):734-736.
58. Ramrakha-Jones VS, Herd RM. Treating Bowcn's disease: a cost-minimization study. Br J Dermatol 2003; 148(6):1167-1172.
59. Cohen PR. Bowens disease: squamous cell carcinoma in situ. Am Fam Physician 1991; 44(4): 1325-1329.
60. Staibano S, Lo Muzio L, Pannone G et al. DNA ploidy and cyclin Dl expression in basal cell carcinoma of the head and neck. Am J Clin Pathol 2001; 115(6):805-813.
61. Frentz G, Moller U. Clonal heterogeneity in curetted human epidermal cancers and precancers analysed by flow cytometry and compared with histology. Br J Dermatol 1983; 109(2): 173-181.
62. Fortier-Beauheu M, Laquerriere A, Thomine E et al. DNA flow-cytometric analysis of basal cell carcinomas and its relevance to their morphological differentiation: a retrospective study. Dermatology 1994; 188(2):94-99.
63. Pilch H, Weiss J, Heubner C et al. Differential diagnosis of keratoacanthomas and squamous cell carcinomas: diagnostic value of DNA image cytometry and p53 expression. J Cutan Pathol 1994; 21(6):507-513.
64. Bicsterfeld S, Pennings K, Grussendorf-Conen EI et al. Aneuploidy in actinic keratosis and Bowens disease-increased risk for invasive squamous cell carcinoma? Br J Dermatol 1995; 133(4):557-560.
65. Kawara S, Takata M, Takchara K. High frequency of DNA aneuploidy detected by DNA flow cytometry in Bowens disease. J Dermatol Sci 1999; 21(l):23-26.
66. Jin Y, Mertens F, Persson B et al. Nonrandom numerical chromosome abnormalities in basal cell carcinomas. Cancer Genet Cytogenet 1998; 103(l):35-42.
67. Jin Y, Martins C, Salemark L et al. Nonrandom karyotypic features in basal cell carcinomas of the skin. Cancer Genet Cytogenet 2001; 131(2):109-119.
68. Casalone R, Mazzola D, Righi R et al. Cytogenetic and interphase FISH analyses of 73 basal cell and three squamous cell carcinomas: diflferent findings in direct preparations and short-term cell cultures. Cancer Genet Cytogenet 2000; 118(2): 136-143.
69. Jin Y, Merterns F, Persson B et al. The reciprocal translocation t(9;16)(q22;pl3) is a primary chromosome abnormality in basal cell carcinomas. Cancer Res 1997; 57(3):404-406.
70. Kawasaki-Oyama RS, Andre FS, Caldeira LF et al. Cytogenetic findings in two basal cell carcinomas. Cancer Genet Cytogenet 1994; 73(2):152-156.
71. Ashton KJ, Weinstein SR, Maguire DJ et al. Molecular cytogenetic analysis of basal ccU carcinoma DNA using comparative genomic hybridization. J Invest Dermatol 2001; 117(3):683-686.
72. Saridaki Z, Koumantaki E, Liloglou T et al. High frequency of loss of heterozygosity on chromosome region 9p21-p22 but lack of pl6INK4a/pl9ARF mutations in greek patients with basal cell carcinoma of the skin. J Invest Dermatol 2000; 115(4):719-725.
73. Quinn AG, Sikkink S, Rees JL. Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. Cancer Res 1994; 54(17) :4756-4759.
74. Shen T, Park WS, Boni R et al. Detection of loss of heterozygosity on chromosome 9q22.3 in microdissected sporadic basal cell carcinoma. Hirni Pathol 1999; 30(3):284-287.
75. Shanley SM, Dawkins H, Wainwright BJ et al. Fine deletion mapping on the long arm of chromosome 9 in sporadic and familial basal cell carcinomas. Hum Mol Genet 1995; 4(1): 129-133.
76. Jin Y, Jin C, Salemark L et al. Clonal chromosome abnormalities in premalignant lesions of the skin. Cancer Genet Cytogenet 2002; 136(l):48-52.
77. Heim S, Caron M, Jin Y et al. Genetic convergence during serial in vitro passage of a polyclonal squamous cell carcinoma. Cytogenet Cell Genet 1989; 52(3-4): 133-135.
78. Kim DK, Kim JY, Kim HT et al. A specific chromosome aberration in a kcratoacanthoma. Cancer Genet Cytogenet 2003; 142(l):70-72.
79. Mertens F, Heim S, Mandahl N et al. Clonal chromosome aberrations in a kcratoacanthoma and a basal cell papilloma. Cancer Genet Cytogenet 1989; 39(2):227-232.
80. Ashton KJ, Wcinstein SR, Maguire DJ et al. Chromosomal aberrations in squamous cell carcinoma and solar keratoses revealed by comparative genomic hybridization. Arch Dermatol 2003; 139(7):876-882.
81. Clausen OP, Beigi M, Bolund L et al. Kcratoacanthomas frequently show chromosomal aberrations as assessed by comparative genomic hybridization. J Invest Dermatol 2002; 119(6): 1367-1372.
82. Clausen OP, Aass HC, Beigi M et al. Are kcratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol 2006; 126(10):2308-2315.
83. Rehman I, Takata M, Wii YY et al. Genetic change in actinic keratoses. Oncogene 1996; 12(12):2483-2490.
84. Lee HJ, Kim JS, Ha SJ et al. p53 gene mutations in Bowen's disease in Koreans: clustering in exon 5 and multiple mutations. Cancer Lett 2000; 158(l):27-33.
85. Mortier L, Marchetti P, Delaporte E et al. Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the pl6(INK4a) tumor suppressor. Cancer Lett 2002; 176(2) :205-214.
86. Waring AJ, Takata M, Rehman I et aL Loss of heterozygosity analysis of keratoacanthoma reveals multiple differences from cutaneous squamous cell carcinoma. Br J Cancer 1996; 73(5):649-653.
87. Van Gele M, Speleman F, Vandesompele J et al. Characteristic pattern of chromosomal gains and losses in Merkel cell carcinoma detected by comparative genomic hybridization. Cancer Res 1998;58(7):1503-1508.
88. Kaur S, Vauhkonen H, Bohling T et aL Gene copy number changes in dermatofibrosarcoma protuberans-a fine-resolution study using array comparative genomic hybridization. Cytogenet Genome Res 2006; 115(3-4):283-288.
89. Scarisbrick JJ, Woolford AJ, Russell-Jones R et al. Allelotyping in mycosis frmgoides and Sezary syndrome: common regions of allelic loss identified on 9p, lOq and 17p. J Invest Dermatol 2001; 117(3):663-670.
90. Hoefnagel JJ, Dijkman R, Basso K et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005; 105(9):3671-3678.
91. Leonard JH, Leonard P, Kearsley JH. Chromosomes 1, 11 and 13 are frequently involved in karyotypic abnormaUties in metastatic Merkel cell carcinoma. Cancer Genet Cytogenet 1993; 67(l):65-70.
92. Larramendy ML, Koljonen V, Bohling T et al. Recurrent DNA copy number changes revealed by comparative genomic hybridization in primary Merkel cell carcinomas. Mod Pathol 2004; 17(5):561-567.
93. Van Gele M, Leonard JH, Van Roy N et al. Frequent allelic loss at 10q23 but low incidence of PTEN mutations in Merkel cell carcinoma. Int J Cancer 2001; 92(3):409-4l3.
94. Vortmeyer AO, Merino MJ, Boni R et al. Genetic changes associated with primary Merkel cell carcinoma. Am J CUn Pathol 1998; 109(5):565-570.
95. Kiuru-Kuhlefelt S, El-Rifai W, Fanburg-Smith J et al. Concomitant DNA copy number ampUfication at 17q and 22q in dermatofibrosarcoma protuberans. Cytogenet Cell Genet 2001; 92(3-4): 192-195.
96. Nishio J, Iwasaki H, Ohjimi Y et al. Overrepresentation of 17q22-qter and 22ql3 in dermatofibrosarcoma protuberans but not in dermatofibroma: a comparative genomic hybridization study. Cancer Genet Cytogenet 2002;132(2):102-108.
97. Mao X, Lillington D, Scarisbrick JJ et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. Br J Dermatol 2002; l47(3):464-475.
98. Streubel B, Scheucher B, Valencak J et al. Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas. Am J Surg Pathol 2006; 30(4):529-536.
99. Hallermann C, Kaune KM, Gesk S et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6 and MALTl gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol 2004; 123(1):213-219.
100. Gimenez S, Costa C, Espinet B et al. Comparative genomic hybridization analysis of cutaneous large B-cell lymphomas. Exp Dermatol 2005; 14(12):883-890.
101. Santos GC, Zielenska M, Prasad M et al. Chromosome 6p amplification and cancer progression. J Clin Pathol 2007; 60(1): 1-7.
102. Scarisbrick JJ, Woolford AJ, Russell-Jones R et al. Loss of heterozygosity on lOq and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. Blood 2000; 95(9):2937-2942.
103. Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 2003; 306(4) :799-804.
104. Tian F, DaCosta Byfield S, Parks WT et al. Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 2003; 63(23):8284-8292.